Aldeyra Therapeutics Reports 65.2% Reduction in Financial Losses for Q1 2026

Aldeyra Therapeutics, Inc. reported a significant reduction in its financial losses for the first quarter of 2026, with a net loss of $3.5 million compared to a net loss of $9.9 million in the same period of 2025. This represents a 65.2% decrease in losses year-over-year. The company’s operating expenses also saw a notable decline, with research and development costs dropping to $2.4 million from $7.4 million, a decrease of 67.5%. General and administrative expenses were reduced to $1.1 million from $3.0 million, reflecting a 62.1% decrease. The overall loss from operations improved to $3.5 million, down from $10.4 million in the prior year.

In terms of cash flow, Aldeyra reported a net cash outflow of $5.1 million from operating activities for the three months ended March 31, 2026, a significant improvement from the $12.5 million used in the same period in 2025. The company ended the quarter with cash and cash equivalents totaling $65.0 million, down from $70.0 million at the end of 2025. The decrease in cash was attributed to operational expenditures, but the company believes its current cash reserves will be sufficient to fund operations into the second half of 2028.

Strategically, Aldeyra has been focusing on its product pipeline, particularly the late-stage candidate reproxalap, which is being developed for the treatment of dry eye disease. The company entered into an exclusive option agreement with AbbVie Inc. in October 2023, which includes a potential collaboration for the development and commercialization of reproxalap. As of March 31, 2026, Aldeyra recorded $6.0 million in deferred collaboration revenue related to this agreement. However, AbbVie has yet to exercise its option to enter into a collaboration agreement.

Operationally, Aldeyra has made significant changes to its workforce and cost structure, resulting in reduced personnel costs and other operational expenses. The company’s employee headcount and engagement metrics have not been disclosed in the filing, but the reduction in expenses suggests a strategic shift towards more efficient operations. The company continues to evaluate its research and development activities and may need to secure additional funding to support ongoing and future projects.

Looking ahead, Aldeyra acknowledges the need for additional capital to fund its research and development activities, regulatory requirements, and potential commercialization efforts. The company is exploring various financing options, including equity and debt financing, to support its operations. The management remains cautious about the uncertainties associated with drug development and regulatory processes, which could impact future financial performance and operational plans.